Phase II Study of IGEV Followed by Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin Lymphoma.
The standard treatment in patients with refractory or relapsed Hodgkin lymphoma is salvage
chemotherapy followed by autologous transplantation for responsive patients. However, the
standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy
and safety of IGEV regimen in a single-center basis.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete response rate
Ye Guo, MD
China: Ethics Committee